Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. by Thatcher, N. et al.
Br.~~~~~~ ~ ~ ~ J. Cacr(99,6 811TeMcilnPesLd,18
Carboplatin, ifosfamide and etoposide with mid-course vincristine and
thoracic radiotherapy for 'limited' stage small cell carcinoma of the
bronchus
N. Thatcher '4, M. Lind1, R. Stout2, C. Payne3, K.B. Carroll4, C. Campbell4
& H. Moussalli4
'CRC Department of Medical Oncology and 2Department of Radiotherapy, Christie Hospital and Holt Radiwn Institute;
3Department of Medicine, Tameside General Hospital, Ashton; and 'Department of Thoracic Medicine and Surgery,
Wythenshawe Hospital, Manchester, UK.
Sary Forty-two patients with small cell lung cancer were treated with a combination of carboplatin,
ifosfamide and etoposide. Vincristine was given on day 14 of each course, the courses being repeated every 28
days for a maximum of six. Thoracic radiotherapy was given 4 weeks after the last course of chemotherapy
but no prophylactic cranial radiotherapy was administered. Thirty patients had clinically limited stage disease,
the remaining patients having contralateral neck lymphadenopathy and/or pleural effusions. Elevated enzyme
levels (alkaline phosphatase, LDH, ALT, GGT) were noted in 69% of patients. Twenty-four patients (57%)
achieved a complete response (CR) when assessed one month after the end of treatment. A further 21% of
patients had a partial response (PR). Median duration of CR was 14 months and of PR 8 months. Cerebral
metastases were the sole site of relapse in 13% of the CR patients. Myelosuppression was severe with a
median nadir of neutropenia of 0.2 x 109 cellsl- However, 74% of the patient group received all six courses
of chemotherapy and only 16 courses (7%) were delayed because of toxicity. There were three deaths
associated with treatment-related neutropenia. The median survival of the total group was 14 months, with an
actuanal 2 year survival of 37% and a minimum follow-up of 18 months. [A recent analysis, March 1989,
demonstrated a 33%, 2 year wtual survival.]
A number of new agents active against small cell lung cancer
are now available. Carboplatin, unlike cisplatin the parent
analogue, has several advantages. Carboplatin is less emetic
and is without significant nephrotoxicity, neurotoxicity or
ototoxicity (Calvert et al., 1982; Smith et al., 1985; Wiltshaw,
1985). Carboplatin has high activity as a single agent in
small cell lung cancer with a response rate of 60% and 82%
when used with etoposide in previously untreated patients
(Smith et al., 1985, 1987). Myelosuppression was the main
toxicity but treatment was otherwise well tolerated.
Ifosfamide (an isomer of cyclophosphamide) and etoposide
with thoracic radiotherapy has given an overall response rate
of 97% without severe toxicity, and a median survival of 11
months in limited stage patients (Thatcher et al., 1987). The
actual 2-year survival (from a more recent analysis) in the
above group of patients is 22%. The myelosuppressive
carboplatin was therefore combined with the ifosfamide,
etoposide and thoracic radiotherapy. Vincristine was also
given at mid-course to help prevent relapse between
chemotherapy treatments.
Patients and methods
Forty-two patients with histologically proven small cell lung
cancer were treated between August 1985 and May 1986.
Twenty-eight patients were men and 14 were women. The
median age was 54 years with a range of 38-70 years.
Histology was obtained by bronchoscopic examination in
79% of patients. In other patients node biopsy or
thoracotomy was performed. Thirty patients had hilar
and/or mediastinal lymphadenopathy as the only obvious
site of tumour and were of limited stage (LS), defined as
tumour confined to one hemithorax, the mediastinum and
ipsilateral supraclavicular lymph nodes. The other 12
patients although having more extensive disease (ES) (see
Table I) were considered to be of a good prognostic group
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as defined by previous multivariant analysis (Cerny et al.,
1987). In nine patients (21%) the Karnofsky performance
status was good, i.e. >80, and in seven patients (17%) the
score was reduced to 50 or less (Karnofsky et al., 1948).
Treatment regimen
Carboplatin was given at 300mgm-2 as a 1 h i.v. infusion in
500ml of 5% dextrose on day 1. Etoposide was administered
at 120mg m 2 i.v. on days 1 and 2 and 240mgm-2 orally
on day 3. Ifosfamide 5gm2 with the same dose of mesna
was given immediately after the carboplatin as a 24h, 21, N
Table I Pretreatment clinical features of the 42 patients
LS (30) ES (12)
Interval from symptoms to diagnosis
< 1-3 months
3-6 months
>6 months
Interyal from diagnosis to treatment
< I month
1-2 months
>2 months
Weight loss (>10% over 6 months)
Superior vena caval obstruction/stridor
Lymphadenopathy
Hilar
Mediastinal
Ipsilateral SCF
Contralatral/cervical
Pleural effusion
Elevated enzymes
Alkaline phosphatase
Lactate dehydrogenase
ALT/GGT
Normal enzyme levels
Karnofsky performance median (and range)
LS, limited stage; ES, extensive stage.
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saline i.v. infusion. A further infusion (11) of Mesna,
3gm-2, was continued over the subsequent 12h. Vincnstine
0.5mgm2 i.v. was given on day 14 (mid-course). Treatment
was repeated every 4 weeks for a maximum of six courses.
No dose reductions were undertaken but treatment was
deferred to allow blood count recovery if platelets were less
than 100,000p1- or white count was less than 3,000
cellsp1y . Lorazepam I mg i.v. was prescribed and if
required metoclopramide, to control nausea and vomiting.
Thoracic megavoltage radiotherapy was given to 36
patients 4-5 weeks after the last course of chemotherapy.
The post-chemotherapy volume was irradiated with a margin
of at least 2cm around any residual disease, to include the
mediastnum and supraclavicular fossa (SCF) if disease was
identified on presentation. In patients with complete radio-
logical response, the field was centred on the site of the
original thoracic tumour. Two treatment schemes were
employed: (a) 75% of patients received a single fraction of
12.5Gy using a 360- rotation technique; the median field size
was lOx9x9cm; (b) the other 25% in whom rotation was
not technically feasible received 27.5Gy midline dose in eight
fractions over 10 days using a parallel opposed pair with a
median field size of 12 x 9cm. Two other patients because of
extensive disease received wide field thoracic radiotherapy.
The remaining four patients were not irradiated, having died
before the completion of chemotherapy. A separate matched
single field of 12.5Gy in one fraction was prescribed for
SCF disease.
Investigations before and during treatment
All patients had a complete clinical examination with chest
radiograph, full blood count and routine biochemistry
including hepatic enzymes before each treatment together
with evaluation of the Karnofsky and Respiratory scores
(Karnofsky et al., 1948; Medical Research Council Lung
Cancer Working Party, 1979). Bone marrow examination,
radionucleide and ultrasound scans were performed before
the first chemotherapy course to confirm clinical or bio-
chemical abnormalities suggestive of metastatic disease. If
these scan or marrow examinations indicated metastatic
disease the patient was not entered into the study. Patients
with brain metastases, with Karnofsky scores of 30 or less,
those aged over 70 years or more and patients previously
treated with chemotherapy and radiotherapy were ineligible
for the study. Repeat bronchoscopy was also requested 4-6
weeks after thoracic radiotherapy.
Toxicity was graded according to standard WHO criteria
(Miller et al., 1981) except for nausea and vomiting which
was scored according to Smith et al. (1987). The nadir blood
count was taken from weekly counts after chemotherapy. If
disease progrssed the treatment protocol was discontinued
and symptomatic measures were instituted.
Table H Response, relapse, progression status and stage
NR PR CR NE
LS ES LS ES LS ES LS
Patient numbers 6 2 7 2 16 8 1
Alive
No relapse/progression - - - - 8 4 1
Relapse/progression - - - - 2 -
Dead
Not of lung carcinoma 2 1 1 - -
Of lung carcinomaa 4 1 6 2 6 4 -
LS, limited stage; ES, extensive stage; NR, non-responder, PR,
CR, partial, complete responders; NE, not evaluable for response.
'Includes relapsed patients and patients with progressive tumour.
33%) had a partial response and in five patients there was
progressive tumour. The remaining three patients died of
probable infection and leucopenia. The median duration of
partial response was 8 months (range 5-13 months) and of
complete response 14 months (range 8-26+ months). Of the
patients who eventually responded, 81% had shown a
response with the first chemotherapy course and the
remainder by the third course. Eighteen patients in clinical
and radiological complete remission agreed to be
rebronchoscoped and in 17 no evidence of tumour was
found.
The median survival of all 42 patients was 14 months
(range 1-26+ months, see Figure 1). The actuarial 2-year
survival is 37% (95% confidence limits for 24 months are
21.5-50.1 by the Greenwood formula with the Kalbfleisch
Prentice adjustment). The median survival of the 30 limited
stage patients was again 14 months with the same range and
two year actuarial survival. The median survival for patients
undergoing partial response was 11 months (range 6-14
months) and for non-responders I month (range <1-7
months). The median survival for complete responders has
not yet been reached. Of the five patients alive at two or
more years, four were of limited stage with no supra-
clavicular lymphadenopathy and the other had a pleural
effusion: the median Karnofsky score was 70 (range 50-80)
and the LDH was raised in three patients including also one
patient with an elevated alkaline phosphatase.
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Follow-up
At the end of treatment patients were seen at monthly
intervals for 4 months then 3-monthly for a year and every 6
months thereafter. Assessment for objective response was
undertaken at first follow-up (I month after the end of
treatment) and was determined by standard criteria (Miller
et al., 1981).
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Results
Response and survival
Twenty-four patients or 57% (95% confidence limits, 42-
72%) of the total patient group were classified as in
complete response one month after the end of treatment
(Table II). One other patient who had had a
pneumonectomy was not radiologically evaluable for
response but was free of tumour at rebronchoscopy at the
end of treatment.
Another nine patients (21%, 95% confidence limits, 9-
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0
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Figwe I Survival of total patient group (n=42; ) and of
the Limited Stage group (n=30; ---).
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Relapse
Twenty patients have developed recurrent tumour following
response (Table II). Of the 12 patients who had a complete
response, one patient had local relapse only within or
adjacent to the irradiated zone, a further five patients had
distant relapse only and the remaining six patients had a
combination of both local and distant relapse. There were
eight patients with a partial response who relapsed, one
locally only, six with distant metastases and the remaining
patient both locally and distantly. Three patients in the
complete responder group developed brain metastases as the
apparent sole site of recurrence. The pattern of relapse is
given in further detail in Table III. Six patients recieved
radiotherapy for relapse and five patients further chemo-
therapy with an adriamycin regimen.
Toxicity
Thirty-one patients (74%) received all six courses of
chemotherapy, six patients four courses and two patients five
courses. One patient received three courses and two patients
one course only. A total of 225 courses (89%) of the possible
maximum 252 courses was therefore administered. Fifteen
courses were delayed by I week and one course by 2 weeks
because of toxicity. The tendency for an increase in
haematological toxicity with increasing number of courses
can be seen in Table IV. On 50 occasions blood transfusions
were given accounting for 167 units of packed cells. Severe
thrombocytopenia requiring platelet transfusions occurred on
11 occasions. On 13 occasions severe or life-threatening
leucopenia (WBC < 1.9 x 109 cells 1 ') was noted 4 weeks
after a chemotherapy course. The marked neutropenia with a
median of 0.2 x 106 neutrophilsI- occumrng 2 weeks after
chemotherapy is shown in Figure 2. On three occasions
infection was thought to have contributed to treatment
related death. One patient who was hypertensive developed
severe renal impairment following the first treatment. No
other renal or urothelial toxicity was noted although partial
alopecia was universal. On only seven courses was there
severe nausea and vomiting requiring anti-emetics for more
than 24h and on 47 courses nausea and vomiting was of
moderate grade. Transient oesophagitis occurred in the
majority of patients but there was no unusual toxicity from
the radiotherapy. The overall improvement in Karnofsky
and Respiratory score with treatment can be seen in
Table V.
Table III Sites of distant relapse
PR CR
Nodes
SCF 1 -
Upper abdomen - 2 (1)
Contralateral lung 1
Brain 7 (4) 8 (3)
Liver 1 3 (1)
Bone
Skin - I
SCF, supraclavicular fossa. Patients without local relapse
in primary tumour area but with single site of metastasis
indicated in parentheses.
Table IV Haematological toxicity
A combination of carboplatin, ifosfamide and etoposide with
mid-course vincristine is an effective combination for small
cell lung cancer. The objective response rate was 78% for the
total patient group and 90% for the 38 patients evaluable
for response at the end of treatment. The response rate is
similar to that found with carboplatin and etoposide used as
first-line treatment described by Smith et al. and our earlier
ifosfamide and etoposide combination (Smith et al., 1987;
Thatcher et al., 1987). The median survival of 14 months is
better than the 9.5 months and 11 months previously
described with the two agent combinations in similar patient
groups (Smith et al., 1987; Thatcher et al., 1987).
Furthermore, the improved median survival and actuarial 2
years survival of 37% was observed in a patient group which
included pleural effusions, contralateral lymph nodes and
elevated hepatic enzymes.
Myelosuppression was a serious problem and three
patients died (with no evidence of tumour), probably from
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Figure 2 Median neutrophil count during chemotherapy.
Table V Change in Karnofsky performance (KP) score and
respiratory assessment score (RA) with treatment
Score after
CT course
Pretreatment 2 4 Post-treatment
KP score
<50k 2% 5% 7% 14%
50-70 77% 17% 10% 7%
80-100 21"% 78% 83% 79%
RA score
1,2 21g% 83% 84% 78%
3,4 62% 12% 9% 7%
Sa 17% 5% 7% 15%
'Includes patients dying.
Grade 1,2 climb hills, stairs, walk any distance on the flat at
normal pace, without dyspnoea; grade 3,4 walk more than 100 yards
at own speed without dyspnoea, dyspnoea on walking 100 yards or
less. Grade 5, dyspnoea on mild exertion, e.g. undressing.
-worst grade based on nadir counts
Course no. 1 2 3 4 5 6
Hb WBC Plat Hb WBC Plat Hb WBC Plat Hb WBC Plat Hb WBC Plat Hb WBC Plat
Grade 0 16 1 12 9 2 15 6 1 12 4 - 4 2 1 3 1 1 5
1 15 - 3 11 1 3 11 1 5 13 - 4 8 - - 9 - 2
2 10 10 13 18 6 6 14 8 5 12 5 7 18 2 7 18 4 5
3 1 25 10 3 22 10 8 19 7 10 16 11 4 15 7 2 13 6
4 - 6 4 0 10 7 1 11 11 - 18 13 1 15 16 - 12 12
NA/NK - - - 1 1 1 2 2 2 3 3 3 9 9 9 12 12 12
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infection and neutropenia. However, the myelosuppression
was transient and only 7% of all courses were delayed due
to toxicity, and no dosage reductions were made. There was
no evidence of nephrotoxicity except in one patient and
treatment had to be discontinued due to renal failure
following the first course. In no other patient was elevation
of serum creatinine noted, and lack of nephrotoxicity
compared with cisplatin was confirmed.
The incorporation of vincristine between treatment courses
may have prevented the between course relapse described by
Smith et al. (1987) and brain metastases may have been
reduced by prophylactic cranial irradiation. Future studies
using haemopoietic stimulating factors may well reduce
myelosuppression and allow further development of chemo-
therapeutic strategies.
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